BI And Lilly Eye Acute Heart Failure Opportunity For Jardiance
First SGLT Inhibitor To Work In These Patients
Executive Summary
Having strongly made the case for Jardiance as a treatment for chronic heart failure, Boehringer Ingelheim and Eli Lilly believe the SGLT2 inhibitor could have a lot of potential in acute heart failure as well after promising data from the EMPULSE study.
You may also be interested in...
Lilly Looks To Volume-Driven Growth In Decade Ahead
CEO Dave Ricks told investors Lilly will succeed via volume-driven growth of nine key products launched since 2019, which its commitment to lower prices will facilitate.
Novartis Cites ‘Same Labelling’ Rule In FDA Entresto Petition
Ahead of a proposed patent infringement trial set for September 2022, Novartis is urging the FDA not to approve any generic versions of its blockbuster heart failure therapy Entresto before February 2024 at the earliest, in part because of the agency’s own ‘same labelling’ regulations for ANDA products.
BI/Lilly's Jardiance Enters US Heart Failure Market Fray
Boehringer Ingelheim and Eli Lilly have gained a US approval for their SGLT2 inhibitor empagliflozin in heart failure with reduced ejection fraction, which could be extended further in coming months to other types of heart failure, adding to the products competing in this previously neglected therapeutic area.